Quote:

---

Plaque psoriasis and COVID are two very different conditions

---

Yes of course, understood. My only point was that once a drug is approved in a country, receiving approval for a second indication in that country can be a much smaller effort.

WIth Leronlimab, we still need significant empirical data to clear that initial hurdle.